US Pharma MarketingFDA conveys tougher clamp down of foreign trial data coinciding with China’s rise
FDA leaders defend rigorous review of foreign trial data and double their China inspectors as lawmakers push to counter Beijing Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in…
Top FDA leaders are doubling down on clinical trial oversight measures to ensure that research data generated outside the US are adequate, as lawmakers and some inside the drug industry try to counter China’s growing ...
Source: Endpoints News